UNSPSC 51372120: Dihydrocodeine thiocyanate

This classification denotes an opioid receptor agonist and opioid C18H23NO3.CHNS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 442C0H2H3P, chemically known as morphinan-6-ol, 4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.,6.alpha.)-, thiocyanate (salt), but more generally known as dihydrocodeine thiocyanate, which bears US NIH Compound Identifier 46174078. European Medicines Agency schedules Dihydrocodeine thiocyanate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01707MIG.

Most nations, for tariff and trade purposes, schedule dihydrocodeine thiocyanate under HS 29391100 and SITC 54141. As of Q4 2014, DIHYDROCODEINE THIOCYANATE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](CC[C@H]3[C@H]1C5)O)OC.C(=N)=S.

UNSPSC 51372120 Dihydrocodeine thiocyanate is a Commodity code that shows minimal recent activity aligned with its nominal scope; the posted opportunities under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals, none of which are dihydrocodeine thiocyanate specifically. State and local governments buying under this code would be seeking opioid pharmaceutical products for public health, corrections, emergency response, or clinical settings, but the recent solicitations do not reflect procurement of this specific controlled substance. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance). The geographic activity centers on Florida, Texas, and Minnesota, with broader multi-state reach through the MMCAP cooperative vehicle.

The most recent opportunities posted under this code are Seminole County's IFB60459723LAS (naloxone and drug deactivation systems, response due July 26, 2023, though posted June 30, 2026), the Texas HHS Commission's RFI HHS0017013 (therapeutic pharmacy initiative direct-to-manufacturer prescriptions, response due April 3, 2026), and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (response due March 26, 2026, effective July 1, 2026 through June 30, 2028). The code shows little relevant recent activity for dihydrocodeine thiocyanate procurement itself; opportunities tagged under it reflect broader pharmaceutical and controlled-substance sourcing rather than this specific medication. Vendors pursuing this code should verify the actual pharmaceutical products required in each solicitation before responding, as tagging mismatches are evident in the recent record.